| Literature DB >> 36225858 |
Hanifah Nantongo1,2, Ronald Kiguba2, Vincent Batwala3,4, Jackson Mukonzo2.
Abstract
Purpose: Antimicrobial resistance is now one of the leading five causes of death globally. This study evaluated the rationality of antibiotic prescriptions at lower primary care levels in three districts of Southwestern Uganda.Entities:
Keywords: antibiotic prescriptions; antibiotic resistance; inappropriate
Year: 2022 PMID: 36225858 PMCID: PMC9549792 DOI: 10.2147/JMDH.S384297
Source DB: PubMed Journal: J Multidiscip Healthc ISSN: 1178-2390
Prescription Features Evaluated and Some Demographics
| Feature | Overall n (%) |
|---|---|
| 9899 | |
| Yes | 9462 (95.7) |
| No | 427 (4.3) |
| Yes | 9641 (97.4) |
| No | 196 (2.0) |
| Missing data | 62 (0.6) |
| Yes | 9260 (93.6) |
| No | 568 (5.7) |
| Missing data | 70 (0.7) |
| Yes | 8874 (89.6) |
| No | 956 (9.7) |
| Missing data | 69 (0.7) |
| Yes | 8158 (82.4) |
| No | 1741 (17.6) |
| Yes | 8737 (88.2) |
| No | 897 (9.1%) |
| Missing data | 265 (2.7) |
| Yes | 8883 (89.7) |
| No | 1016 (10.0) |
| Yes | 916 (46.5) |
| No | 1054 (53.5) |
| Yes | 8561 (86.5) |
| No | 1301 (13.1) |
| Missing data | 37 (0.4) |
| Yes | 9596 (96.9) |
| No | 303 (3.1) |
| Yes | 1817 (18.4) |
| No | 8082 (81.6) |
| Yes | 9083 (91.8) |
| No | 814 (8.2) |
| Yes | 9677 (97.8) |
| No | 221 (2.2) |
| Yes | 219 (2.2) |
| No | 9637 (97.4) |
| Missing data | 43 (0.4) |
| Phase 1 | 3408 (34.4) |
| Phase 2 | 3108 (31.4) |
| Phase 3 | 3383 (34.2) |
| Health center II | 3845 (38.9) |
| Health center III | 4072 (41.1) |
| Health center IV | 1982 (20.0) |
| Mbarara | 3331 (33.7) |
| Bushenyi | 3724 (37.6) |
| Kasese | 2844 (28.7) |
| Pediatrics (age ≤12 years) | 1970 (19.9) |
| Adults (age > 12 years) | 6913 (69.8) |
| Age not recorded | 1016 (10.3) |
| Present | 6820 (69.1) |
| Not present | 3045 (30.9) |
| Medical Officer | 252 (2.5) |
| Clinical Officer | 2436 (24.6) |
| Registered Nurse/midwife | 1092 (11.0) |
| Enrolled Nurse | 4661 (47.1) |
| Enrolled Midwife | 229 (2.3) |
| Nursing Assistant | 552 (3.9) |
| Other | 401 (5.6) |
| Designation not recorded | 276 (2.8) |
| Rational | 3387 (34.2) |
| Irrational | 6512 (65.8) |
| 5 (5–5) |
Factors Associated with Prescription Rationality
| Factors | Prescription Rationality | |||
|---|---|---|---|---|
| Rational n(%) | Not Rational | Crude OR (95% CI) | Adj. OR (95% CI) | |
| n(%) | ||||
| Phase 1 | 1108 (32.5) | 2300 (67.5) | 1.00 | 1.00 |
| Phase 2 | 1070 (34.4) | 2038 (65.6) | 1.09 (0.98–1.21) | 1.14 (1.02–1.28)* |
| Phase 3 | 1209 (35.7) | 2174 (64.3) | 1.15 (1.04–1.28)** | 1.23 (1.1–1.38)*** |
| Health center II | 1326 (34.5) | 2519 (65.5) | 1.00 | |
| Health center III | 1367 (33.6) | 2705 (66.4) | 0.96 (0.87–1.05) | |
| Health center IV | 694 (35.0) | 1288 (65.0) | 1.02 (0.91–1.15) | |
| Mbarara | 1315 (39.5) | 2016 (60.5) | 1.00 | 1.00 |
| Bushenyi | 1164 (31.3) | 2560 (68.7) | 0.70 (0.63–0.77)*** | 0.65 (0.58–0.73)*** |
| Kasese | 908 (31.9) | 1936 (68.1) | 0.72 (0.65–0.80)*** | 0.70 (0.62–0.79)*** |
| Yes | 3287 (34.7) | 6175 (65.3) | 1.00 | 1.00 |
| No | 96 (22.5) | 331 (77.5) | 0.54 (0.43–0.69)*** | 0.61 (0.47–0.78)*** |
| Pediatrics (age ≤12 years) | 888 (45.0) | 1085 (55.0) | 1.00 | – |
| Adults (age > 12 years) | 2467 (35.7) | 4446 (64.3) | 0.82 (0.75–0.89)*** | – |
| Present | 2356 (34.5) | 4464 (65.5) | 1.00 | |
| Not present | 1024 (33.6) | 2021 (66.4) | 0.96 (0.88–1.05) | |
| MO | 123 (48.8) | 129 (51.2) | 1.00 | 1.00 |
| CO | 853 (35.0) | 1583 (65.0) | 0.57 (0.44–0.73)*** | 0.72 (0.54–0.95)* |
| RN | 356 (32.6) | 736 (67.4) | 0.51 (0.38–0.67)*** | 0.63 (0.46–0.86)** |
| EN | 1564 (33.6) | 3097 (66.4) | 0.53 (0.41–0.68)*** | 0.61 (0.46–0.81)** |
| EM | 72 (31.4) | 157 (68.6) | 0.48 (0.33–0.70)*** | 0.41 (0.27–0.62)*** |
| N/Assistant | 165 (29.9) | 387 (70.1) | 0.45 (0.33–0.61)*** | 0.47 (0.33–0.66)*** |
| Other | 153 (38.2) | 248 (61.8) | 0.65 (0.47–0.89)** | 0.78 (0.55–1.11) |
| Amoxycillin | 2126 (48.4) | 2271 (51.6) | 1.00 | 1.00 |
| Metronidazole | 452 (18.8) | 1954 (81.2) | 0.25 (0.22–0.28)*** | 0.23 (0.21–0.27)*** |
| Ciprofloxacin | 324 (35.5) | 588 (64.5) | 0.59 (0.51–0.68)*** | 0.54 (0.47–0.63)*** |
| Doxycycline | 103 (13.8) | 645 (86.2) | 0.17 (0.14–0.21)*** | 0.14 (0.12–0.18)*** |
| Others | 225 (36.7) | 388 (63.3) | 0.62 (0.52–0.74)*** | 0.48 (0.40–0.58)*** |
| Present | 3333 (34.6) | 6308 (65.4) | 1.00 | 1.00 |
| Not present | 42 (21.4) | 154 (78.6) | 0.52 (0.37–0.73)*** | 0.56 (0.38–0.81)** |
| Present | 3248 (35.1) | 6012 (64.9) | 1.00 | – |
| Not present | 119 (21.0) | 449 (79.0) | 0.49 (0.40–0.60)*** | – |
| Present | 3093 (34.9) | 5781 (65.1) | 1.00 | – |
| Not present | 278 (29.1) | 678 (70.9) | 0.77 (0.66–0.89)*** | – |
| Given | 84 (38.4) | 135 (61.6) | 1.00 | |
| Not given | 3297 (34.2) | 6340 (65.8) | 0.84 (0.63–1.10) | |
Notes: – Variable dropped from the model due to lost statistical significance at multivariable analysis. *0.05>p-value≥0.01. **0.01>p-value≥0.001. ***p-value<0.001.